Protective and Damaging Mechanisms of Neuromelanin‐Like Nanoparticles and Iron in Parkinson's Disease
Source abstract
Abstract
Abstract Parkinson's disease (PD) pathology speculates that neuromelanin (NM) and iron ions play a significant role in physiological and pathological conditions of PD. Because the difficult accessibility of NM has limited targeted research, synthetic melanin‐like nanoparticles have been used to instead. In this report, the eumelanin and pheomelanin‐like polydopamine (PDA) nanoparticles are prepared that can be used to simulate natural NM with or without chelating iron ion and studied the redox effects in vitro and in vivo on neuronal cells and PD. The synthetic pheomelanin‐like PDA nanoparticles have much stronger redox activity than eumelanin‐like PDA nanoparticles without or with iron ion. They can protect neurons by scavenging reactive oxygen species (ROS), while cause neuronal cell death and PD due to excessive binding of iron ions. This work provides new evidence for the relationship among two structural components of NM and iron in PD as well as displays the different effects on the roles of eumelanin and pheomelanin in redox activity under physiological or pathological conditions, which provide a new effective choice for cellular and animal models of PD and offer theoretical guidance for targeted treatment and mechanism research on PD.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Parkinson's Disease Mechanisms and Treatments · melanin and skin pigmentation · Synthesis of Organic Compounds
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
The Higher Educational Key Laboratory for Biomedical Engineering of Fujian Province/Research Center of Biomedical Engineering of Xiamen Fujian Key Laboratory of Surface and Interface Engineering for High Performance Materials Department of Biomaterials College of Materials Xiamen University Xiamen 361005 China
Funding
National Natural Science Foundation of China
References (55)
Show source-provided references
1. 10.1038/nrdp.2017.1310.1038/nrdp.2017.13 ↗
2. 10.1016/S1474-4422(18)30322-310.1016/S1474-4422(18)30322-3 ↗
3. 10.1038/nrn.2016.17810.1038/nrn.2016.178 ↗
4. 10.1016/S0140-6736(21)00218-X10.1016/S0140-6736(21)00218-X ↗
5. 10.1038/nrn153710.1038/nrn1537 ↗
6. 10.1007/s12640-013-9435-y10.1007/s12640-013-9435-y ↗
7. 10.1073/pnas.060401010310.1073/pnas.0604010103 ↗
8. 10.1111/j.1751-1097.2007.00238.x10.1111/j.1751-1097.2007.00238.x ↗
9. 10.1007/s12640-013-9435-y10.1007/s12640-013-9435-y ↗
10. 10.1016/S0014-5793(01)03269-010.1016/S0014-5793(01)03269-0 ↗
11. 10.1016/j.pneurobio.2015.09.01210.1016/j.pneurobio.2015.09.012 ↗
12. 10.1021/jacs.0c1232210.1021/jacs.0c12322 ↗
13. 10.1126/science.114724110.1126/science.1147241 ↗
14. 10.1021/bm101281b10.1021/bm101281b ↗
15. 10.1021/acsnano.6b0550210.1021/acsnano.6b05502 ↗
16. 10.1002/adma.20120468310.1002/adma.201204683 ↗
17. 10.1016/j.biomaterials.2015.11.03710.1016/j.biomaterials.2015.11.037 ↗
18. 10.7150/thno.1443110.7150/thno.14431 ↗
19. 10.1021/acsami.2c0698110.1021/acsami.2c06981 ↗
20. 10.1021/acschemneuro.6b0023110.1021/acschemneuro.6b00231 ↗
21. 10.1002/anie.20220478710.1002/anie.202204787 ↗
22. 10.1073/pnas.79.9.288510.1073/pnas.79.9.2885 ↗
23. 10.1016/j.actbio.2019.02.03210.1016/j.actbio.2019.02.032 ↗
24. 10.1016/j.electacta.2018.10.11910.1016/j.electacta.2018.10.119 ↗
25. Forooshani P. K. · Front. Chem. · 2019 · 7
26. 10.1111/j.1471-4159.2008.05541.x10.1111/j.1471-4159.2008.05541.x ↗
27. 10.1073/pnas.040349510110.1073/pnas.0403495101 ↗
28. 10.1021/ac801817k10.1021/ac801817k ↗
29. 10.1046/j.1471-4159.2003.01923.x10.1046/j.1471-4159.2003.01923.x ↗
30. 10.1007/s00702-006-0453-210.1007/s00702-006-0453-2 ↗
31. 10.1093/brain/awab19110.1093/brain/awab191 ↗
32. 10.1021/bm400813810.1021/bm4008138 ↗
33. 10.1021/acsbiomaterials.9b0046110.1021/acsbiomaterials.9b00461 ↗
34. 10.1039/C7MT00244K10.1039/C7MT00244K ↗
35. 10.1016/j.bbabio.2011.03.01310.1016/j.bbabio.2011.03.013 ↗
36. 10.1039/C6RA07091D10.1039/C6RA07091D ↗
37. 10.1021/acsnano.1c0045310.1021/acsnano.1c00453 ↗
38. 10.1007/s12035-016-0266-810.1007/s12035-016-0266-8 ↗
39. 10.1186/s12929-023-00961-z10.1186/s12929-023-00961-z ↗
40. 10.4103/1673-5374.37138110.4103/1673-5374.371381 ↗
41. 10.1016/j.freeradbiomed.2023.08.02110.1016/j.freeradbiomed.2023.08.021 ↗
42. 10.1016/j.arr.2021.10126310.1016/j.arr.2021.101263 ↗
43. 10.1016/j.jinorgbio.2008.09.00710.1016/j.jinorgbio.2008.09.007 ↗
44. 10.3390/antiox1001012410.3390/antiox10010124 ↗
45. 10.1007/s00702-013-1062-510.1007/s00702-013-1062-5 ↗
46. 10.3390/antiox912128510.3390/antiox9121285 ↗
47. 10.1038/nrneurol.2014.22810.1038/nrneurol.2014.228 ↗
48. 10.1016/j.cmet.2015.06.00610.1016/j.cmet.2015.06.006 ↗
49. 10.1016/j.nbd.2015.02.03010.1016/j.nbd.2015.02.030 ↗
50. 10.2217/nnm-2016-034210.2217/nnm-2016-0342 ↗
51. 10.15252/emmm.20150574810.15252/emmm.201505748 ↗
52. Chang H. C. · Circ. Res. · 2015 · 117 · 115
53. 10.1186/1743-0003-2-2010.1186/1743-0003-2-20 ↗
54. 10.1007/s00204-016-1757-010.1007/s00204-016-1757-0 ↗
55. 10.1007/s12640-009-9140-z10.1007/s12640-009-9140-z ↗